Autoinflammatory syndromes (AIS) are a group of disorders characterized by recurrent episodes
of inflammation.Although for the hereditary autoinflammatory diseases the genetic mutations
are known it remains largely unclear how these mutations lead to recurrent inflammatory
attacks. Treatment of the inflammatory symptoms remains a challenge. With beneficial
responses reported during treatment with simvastatin, etanercept or anakinra in some but not
all patients. ITF2357 is an orally active histon deacetylase inhibitor with a potent
anti-inflammatory effect due to inhibition of pro-inflammatory cytokines (IL-1β, TNFα, IFNg,
IL-6). We expect that ITF2357 is able to modify the clinical symptoms of AIS patients and
induce clinical complete remission or a reduction in attack duration.